In this study, we investigated for the first time the role of both ZEB1 and ZEB2 in docetaxel‐resistant prostate cancer and provide strong evidence for ZEB1, through its transcriptional repression of E‐cadherin to be a driver of both EMT and docetaxel resistance. This evidence concerns the gene ZEB2 and prostate carcinoma.